GLP-1 receptor agonists are most often discussed in the context of weight loss. However, growing evidence shows they can also support cardiovascular health. For providers interested in offering compounded semaglutide and tirzepatide, understanding these added benefits can help shape patient selection and treatment goals.
Vigor Compounding supports providers offering GLP-1 therapies by working with trusted, licensed 503A compounding pharmacy partners. These programs are designed to help practices integrate compounded GLP-1 options into patient care models in a compliant and quality-focused way.
GLP-1s and Heart Health: What the Data Shows
GLP-1 receptor agonists mimic natural incretin hormones that regulate blood sugar and appetite. These medications slow gastric emptying, reduce food intake, and support insulin secretion.
In addition to metabolic improvements, they have been shown to reduce key cardiovascular risk factors. This includes systolic blood pressure, LDL cholesterol, and inflammatory markers such as C-reactive protein.
A study published by the New England Journal of Medicine evaluated patients with type 2 diabetes and high cardiovascular risk. Those who received semaglutide once a week demonstrated reduced rates of major adverse cardiovascular events (MACE), including stroke and myocardial infarction.
Another study published by The Lancet assessed individuals who were overweight or obese with established cardiovascular disease (but did not have diabetes). This study showed a 20 % reduction in MACE when patients were treated with semaglutide compared to a placebo.
These findings suggest a potential cardioprotective effect, especially for patients with obesity, insulin resistance, or metabolic syndrome.
Clinical Relevance for Providers Prescribing GLP-1 Therapies
For patients with excess weight and a history of cardiovascular disease — or risk factors like hypertension or dyslipidemia — GLP-1 therapy may support more than weight loss alone. Providers can consider these agents as part of a comprehensive approach to mitigate long-term health risks.
When discussing treatment options, patients often focus on pounds lost. Framing the conversation around improved heart health, blood pressure control, and inflammatory regulation can help them understand the full benefit of staying consistent with treatment.
Partner With a Compounding Pharmacy That Prioritizes Outcomes
Given limited access to commercial GLP-1 drugs, compounding therapies have become a practical alternative. Partnering with trusted, licensed 503A compounding pharmacy partners can help providers maintain confidence in quality standards and consistency while supporting appropriate prescribing workflows.
If you’re ready to offer compounded GLP-1 therapy options to your patients, our team can help connect you with trusted 503A compounding pharmacy partners and compliant support resources. Reach out today to discover how to incorporate GLP-1 therapies into your treatment protocols.
